同步放化疗联合β-榄香烯注射液治疗食管癌临床研究.docVIP

同步放化疗联合β-榄香烯注射液治疗食管癌临床研究 　　[摘要] 目的 评价同步放化疗联合β-榄香烯注射液治疗食管癌的近期和远期疗效及毒副反应。 方法 将84例中晚期食管癌患者随机分成对照组和试验组，每组各42例，试验组采用同步放化疗+β-榄香烯注射液治疗，对照组单纯同步放化疗治疗。 结果 试验组1、2、3年局控率分别为83.3%、71.4%、52.4%，明显高于对照组，差异有统计学意义（P 0.05）。 结论 β-榄香烯注射液对食管癌同步放化疗具有协同作用，可提高食管癌患者局控率及生存率，且并不增加同步放化疗所致的毒副反应。 　　[关键词] β-榄香烯；食管癌；同步放化疗 　　[中图分类号] R735.1 [文献标识码] A [文章编号] 1673-7210（2012）04（a）-0069-03 　　 　　Clinical research of concurrent chemoradiotherapy combined with β-Elemene Injection in the treatment of esophageal cancer 　　ZHOU Jian 　　Department of Oncology, Traditional Chinese Medicine Hospital of Changzhou City, Jiangsu Province, Changzhou 213003, China 　　[Abstract] Objective To evaluate the short-term and long-term efficacy and toxicity of concurrent chemoradiotherapy combined with β-Elemene Injection in the treatment of esophageal cancer. Methods 84 patients with advanced esophageal cancer were randomly divided into experiment group and control group, each group had 42 cases. The experiment group was treated with concurrent chemoradiotherapy+β-Elemene Injection, and the control group was only given radiotherapy and chemotherapy alone. Results In experiment group, the one, two and three-year local control rates were 83.3%, 71.4%, 52.4% respectively, which were significantly higher than those of the control group (P 0.05). Conclusion β-Elemene Injection with a synergy effect when combined with concurrent chemoradiotherapy can improve the local control rate and survival rate in patients with esophageal cancer, and without increasing the adverse reactions induced by concurrent chemoradiationtherapy. 　　[Key words] β-elemene Injection; Esophageal cancer; Concurrent chemoradiotherapy 　　 　　食管癌是一种高度侵袭性的胃肠道恶性肿瘤，就诊时约50%的患者因转移而不能手术切除。即使在能手术治疗的情况下，其5年期生存率也仅为6%~24%[1]。而同步放化疗已成为目前推荐的食管癌标准治疗方法，其治疗的局部缓解率可达到40%~60%[2]。当然，随着临床研究的深入发现，局部中晚期食管癌同步放化疗虽比单纯放疗具有更高的生存优势，但仍有较高的局部复发和远处转移[3]。因此本院尝试着在同步放化疗治疗食管癌的同时使用β-榄香烯注射液治疗，通过观察其近期和远期疗效以及毒副反应，初步探讨β-榄香烯注射液在联合同步放化疗治疗食管癌中的作用以及安全性。 　　1 资料与方法 　　1.1 一般资料 　　选取我院2006年1月~2008年1月